Jan 25, 2020
Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI)
Nov 01, 2019
Taiho Oncology Joins Efforts to Improve Awareness of Gastric Cancer with Support of Leading Advocacy Groups
Aug 29, 2019
Taiho Pharmaceutical Invests in New Venture Capital Fund
Jun 03, 2019
Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Data at the 2019 ASCO Annual Meeting
Mar 01, 2019
Taiho Oncology Announces Support of Colorectal Cancer Awareness Month Through Research and Awareness Initiatives
Feb 25, 2019
FDA Approves Taiho Oncology's LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Feb 05, 2019
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor
Jan 17, 2019
Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)
Oct 21, 2018
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology
Oct 16, 2018
Taiho Ventures Expands Investment Pool to US$300 Million to Continue Quality Investments and Accelerate Open Innovation
Sep 28, 2018
Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium
Jun 21, 2018
Taiho Oncology and Servier Present Data on LONSURF® (trifluridine and tipiracil) at ESMO 20th World Congress on Gastrointestinal Cancer 2018
Jun 07, 2018
Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF® (trifluridine and tipiracil)
May 09, 2018
Taiho Oncology Announces Positive Topline Results from Pivotal Phase 3 Trial of LONSURF® (trifluridine/tipiracil) in Metastatic Gastric Cancer
Jan 03, 2018
Taiho Oncology Names Timothy Whitten President